Stem cell therapy for peripheral neuropathy.

Peripheral neuropathy is damage to the nerves outside the brain and spinal cord. The sensory, motor, and autonomic fibers that carry signals between the body and the central nervous system. The clinical experience ranges from intermittent tingling and numbness to relentless burning pain, balance loss, and progressive functional disability. The underlying biology depends on the cause, but the broad pattern is the same: nerves are losing their ability to do their job, and the body's repair mechanisms are not keeping pace.

Common causes we see clinically

• Diabetic peripheral neuropathy (DPN). The most prevalent form, affecting roughly half of all adults with long-standing diabetes. Driven by chronic hyperglycemia, oxidative stress, and microvascular damage to the vasa nervorum (the small vessels that supply peripheral nerves).^[1]
• Chemotherapy-induced peripheral neuropathy (CIPN). A dose-limiting toxicity of platinum agents, taxanes, vinca alkaloids, and bortezomib. Often persists long after treatment ends, with limited effective therapies.^[2]
• Idiopathic small-fiber neuropathy. A sensory-predominant pattern affecting unmyelinated and thinly myelinated fibers, frequently presenting as burning pain in the feet with normal nerve conduction studies.
• Post-surgical or post-traumatic neuropathy. Localized nerve damage following surgery, injury, or compression.
• Autoimmune and inflammatory neuropathies. CIDP and related entities; treated primarily by neurology, with regenerative protocols only as a possible adjunct after immunomodulation is established.

What current treatments do, and don't do

Standard pharmacotherapy for painful neuropathy (gabapentin, pregabalin, duloxetine, amitriptyline, topical lidocaine) is symptom management. These medications can blunt pain and improve sleep, but none of them repair damaged nerve fibers, restore lost sensation, or address the underlying microvascular and inflammatory drivers. Glycemic control slows progression in diabetes but does not reverse established damage. For CIPN, no FDA-approved disease-modifying therapy exists; current guidelines recommend duloxetine as the only modestly effective symptomatic option.^[2]

This is the gap that regenerative cellular medicine attempts to fill. Modestly, and with evidence still in development.

The biological rationale for mesenchymal stem cell therapy in peripheral neuropathy rests on three converging effects, all driven primarily by paracrine signaling rather than direct cell replacement.^[3]

Nerves repair and remodel over months, not days. The realistic goal is symptom reduction, improved function, and reduced reliance on symptomatic medications. Not a guaranteed cure.

What clinical evidence exists

The clinical evidence base for MSC therapy in diabetic peripheral neuropathy has grown substantially over the past decade. A 2020 systematic review and meta-analysis pooling outcomes across multiple controlled trials reported significant improvements in pain scores, nerve conduction velocity, and patient-reported symptoms compared to standard care, with a favorable safety profile across the analyzed studies.^[5] Individual phase I/II trials of bone marrow-derived and umbilical cord-derived MSCs in DPN have reported similar directional findings.^[6]

For chemotherapy-induced peripheral neuropathy, the published evidence is earlier still. Preclinical work and small case series rather than randomized controlled trials at scale. The mechanistic rationale is similar (inflammation, mitochondrial dysfunction in dorsal root ganglion neurons, vascular damage), but the clinical evidence base is not yet comparable to DPN.

The honest framing. The signals from the published literature are encouraging and consistent in direction, but the field is earlier in its evidence cycle than knee osteoarthritis. Long-term comparative data, optimal dosing, and durability of effect are all still being established. We will discuss what the evidence currently supports for your specific case during the consult. And what it does not.

Patient selection matters more in neuropathy than in joint disease, because the underlying systemic conditions (uncontrolled diabetes, ongoing chemotherapy, untreated autoimmune disease) often need to be addressed first. Regenerative therapy works on a body that has been brought to a stable baseline. It is not a substitute for that work.

What we need to evaluate you

• Diagnosis confirmation. Recent neurology evaluation, EMG/nerve conduction study where appropriate, skin biopsy results if small-fiber neuropathy is suspected.
• Underlying-condition status. HbA1c and metabolic panel for diabetes; oncology summary for CIPN; rheumatology workup if autoimmune.
• Current medications. Gabapentinoids, antidepressants, anticoagulants, immunosuppressants.
• Symptom inventory. Pain pattern, distribution, severity (a baseline VAS or DN4 score), functional impact (balance, sleep, falls).

The consult is complimentary, and if regenerative therapy is not the right answer for your case, we will tell you.

Neuropathy protocols at TrueCell are systemic by design. The disease is distributed along long peripheral nerves, so the delivery has to reach the entire affected territory. That means intravenous as the primary route, with optional adjuncts where a specific anatomical lesion can be targeted.

Baseline workup

Before any infusion, we want a documented baseline so the protocol's effect can be measured honestly. The neuropathy-specific baseline typically includes:

• Pain and symptom scales. Visual analog scale (VAS), DN4 (Douleur Neuropathique 4) or PainDETECT, MNSI (Michigan Neuropathy Screening Instrument).
• Neurological exam. Light touch, vibration (128 Hz), pinprick, monofilament, deep tendon reflexes, balance testing.
• Nerve conduction / EMG if recent results are not already available.
• Metabolic panel. CMP, HbA1c, fasting glucose, lipid panel, hsCRP.
• Vitamin and toxin screen. B12, folate, methylmalonic acid, TSH, and (when indicated) heavy-metal screening.

The cellular intervention

• UC-MSC IV infusion. 50M cells (anti-inflammatory dose) for less-severe presentations or 100M cells (high-dose) for established symptomatic neuropathy. Wharton's jelly umbilical-cord-derived mesenchymal stem cells, prepared in our ISO-accredited laboratory and viability-verified before infusion.
• Muse cell IV. 1.5×10⁷ (standard) or 3.0×10⁷ (high-dose) for patients who may benefit from the homing and stress-tolerance characteristics of this MSC subset.^[7]
• Systemic exosome infusion. The cell-free extracellular-vesicle fraction, used as an adjunct or in patients for whom whole-cell infusion is not appropriate.
• Targeted local injection. For post-surgical or post-traumatic mononeuropathy, image-guided perineural UC-MSC injection at the lesion site can be added to the systemic protocol.

Realistic outcomes, and what this protocol will not do

• The realistic goal is symptom reduction, improved function, and reduced reliance on symptomatic medications. Not a guaranteed cure.
• End-stage sensory loss is unlikely to be reversed.
• This is not a substitute for glycemic control in diabetes, oncology surveillance in cancer survivors, or immunomodulation in autoimmune neuropathy.
• We do not promise an outcome. The evidence base supports a directional case, not a deterministic one.

Safety

Updated systematic reviews of intravenous MSC administration across multiple disease contexts have continued to report favorable safety profiles, with adverse events typically mild, transient, and self-limited.^[8] The most common reactions are short-lived flushing, mild fatigue, or transient low-grade fever in the 24 to 48 hour window. Serious adverse events were rare in the cited datasets. We discuss the protocol-specific risk profile in writing during informed consent, before anything is scheduled.